| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
Anticancer drug 309 can effectively bind purified c-Myc G4 and KRAS G4 structures, with Kd values of 2.46 μM and 1.61 μM, respectively [1]. Anticancer drug 309 (24 h) can inhibit the proliferation of various human and mouse tumor cell lines (MDA-MB-231, HCT116, HepG2, A549, MCF-7, 4T1), with IC50 values ranging from 7.77 ± 0.77 μM to 16.71 ± 0.71 μM [1]. Anticancer drug 309 (10 μM; 24 h) can promote the formation of G4 structures in the nucleus of human breast cancer MDA-MB-231 cells [1]. Anticancer drug 309 (5-20 μM; 24 h) can induce apoptosis in breast cancer MDA-MB-231 cells [1].
|
|---|---|
| ln Vivo |
Anticancer agent 309 (10 mg/kg; once every other day; for 14 consecutive days) has a strong antitumor effect on BALB/c mice carrying 4T1 breast cancer cells, while increasing the number of CD4+ and CD8+ T cells in the spleen and tumor [1].
|
| Animal Protocol |
Animal/Disease Models:BALB/c (female, 4 weeks old, subcutaneously inoculated with 4 × 10⁵ 4T1 mouse breast cancer cells) [1]
Doses: 10 mg/kg Route of Administration: Once every other day for 14 days Experimental Results: Reduced final tumor weight. Inhibited tumor growth. Increased the proportion of CD45⁺CD3⁺CD4⁺ helper T cells in the spleen and tumor. Increased the proportion of CD45⁺CD3⁺CD8⁺ cytotoxic T lymphocytes in the spleen and tumor. Induced downregulation of GPX4 and upregulation of Cleaved Caspase 3 in tumor tissue. No significant decrease in body weight or change in major organ weight in mice compared with the control group. |
| References |
| Molecular Formula |
C31H36N6
|
|---|---|
| Molecular Weight |
492.66
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
CN1CCN(CC1)C2=CC=C(C=C2)C3=C(NC(C4=CC=CC=C4)=N3)C5=CC=C(C=C5)N6CCN(CC6)C
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0298 mL | 10.1490 mL | 20.2980 mL | |
| 5 mM | 0.4060 mL | 2.0298 mL | 4.0596 mL | |
| 10 mM | 0.2030 mL | 1.0149 mL | 2.0298 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
